Amlodipine

Basic amlodipine information

• INN (international nonproprietary name): amlodipine
• Brand names available in the United Kingdom: Istin; generic amlodipine besilate.
• ATC code: C08CA01
• Forms and strengths: tablets 2.5 mg, 5 mg, 10 mg; oral solution (limited availability); fixed-dose combinations with other medicines.
• Manufacturers in the United Kingdom: Pfizer, Accord Healthcare, Sandoz.
• Registration status in the United Kingdom: Amlodipine is marketed in the UK under multiple brands and formulations and is listed in national formularies.
• OTC / Rx classification: prescription only (Rx).

Clinical effectiveness in the UK

Will patients see blood‑pressure improvements within weeks when starting amlodipine?

Amlodipine is one of the most widely used calcium‑channel blockers for hypertension and chronic stable angina in the UK.

Once‑daily dosing and predictable pharmacokinetics support adherence, and many patients have fewer angina attacks and measurable BP reductions after four to eight weeks of treatment.

Real‑world adherence rates vary by cohort and comorbidity, with peripheral oedema a leading cause of dose reduction or stopping the medicine in routine practice.

Amlodipine is effective both as first‑line monotherapy and as add‑on treatment, particularly when ACE inhibitors or ARBs are contraindicated or not tolerated.

Primary care uses shared decision‑making and a stepwise escalation strategy (start 5 mg → increase to 10 mg) with BP monitoring and side‑effect review.

• BP control: improved control is usually seen within 4–8 weeks when used alone or in combination.
• Discontinuation reasons: Peripheral oedema, dizziness and patient preference are the common causes.
• Time to effect: Symptom and BP benefits often measurable by 4 weeks and clearer by 8 weeks.

Indications and expanded uses

What is amlodipine licensed to treat, and are there situations where GPs use it off‑label?

The MHRA‑recognised indications for amlodipine in the UK are essential hypertension and chronic stable or vasospastic angina, and it is a prescription‑only medicine.

In NHS cardiology and general practice, clinicians sometimes use amlodipine off‑label for selected presentations such as microvascular angina or certain vasospastic conditions when other options are unsuitable, with the requirement to document and justify off‑label use.

• MHRA‑approved indications: Essential hypertension; chronic stable angina and vasospastic angina.
• Common off‑label uses: Microvascular angina and selected vasospastic disorders where alternatives are unsuitable and specialist review supports use.

Composition and brand landscape

Which brand or generic should a patient expect to receive from an NHS prescription?

The active substance is amlodipine, commonly supplied as the besilate salt in the UK and marketed under the brand name Istin (Pfizer) alongside multiple generics from manufacturers including Accord and Sandoz.

Tablets are commonly available in 2.5mg, 5mg and 10mg strengths, and are usually supplied in blister packs.

Generics are widely used across NHS primary care, with branded products prescribed less often.

Contraindications and special precautions — who needs extra monitoring

Who should not take amlodipine, and which patients need closer follow‑up?

Absolute contraindications include hypersensitivity to amlodipine or dihydropyridines, severe hypotension, shock (including cardiogenic shock), obstructive outflow tract lesions such as severe aortic stenosis and haemodynamically unstable heart failure following acute myocardial infarction.

Relative cautions include severe hepatic impairment, elderly patients who should start at a lower dose and titrate slowly, severe heart failure and pregnancy or breastfeeding where alternatives may be preferred.

• Absolute contraindications: Hypersensitivity to amlodipine/dihydropyridines; severe hypotension; shock; significant aortic stenosis; haemodynamically unstable heart failure post‑MI.
• Relative precautions: Severe hepatic impairment; advanced age; unstable heart failure; renal impairment requires clinical monitoring though dose changes are not routinely required.

Practical UK advice includes assessing orthostatic risk for those who drive and counselling on alcohol use, which may worsen hypotension and dizziness.

Dosage guidelines

How is amlodipine typically started and adjusted in NHS practice?

Standard adult initiation in NHS practice is 5mg once daily with increase to 10mg once daily if required for blood‑pressure control or angina symptom relief.

Elderly patients and those with hepatic impairment often start at a lower dose (2.5–5mg) and are titrated carefully according to response and tolerability.

Children aged 6–17 years may be dosed at 2.5–5 mg once daily, while children under 6 years are not recommended for routine use.

Missed dose advice: take as soon as remembered unless the next dose is due soon; do not double up.

Interactions overview

Which medicines or foods increase the risk of side effects with amlodipine?

Amlodipine is predominantly metabolised by CYP3A4, so strong CYP3A4 inhibitors can raise plasma concentrations and increase adverse effects such as hypotension and peripheral oedema.

Concomitant use with other antihypertensives may produce additive blood‑pressure lowering and occasional symptomatic hypotension.

Drugs that slow heart rate are less commonly a direct interaction risk with dihydropyridine CCBs, but caution is required if combined with other rate‑lowering agents.

Grapefruit juice in large amounts may influence calcium‑channel blocker metabolism and is best avoided.

• High‑priority interactors: Strong CYP3A4 inhibitors (may increase amlodipine levels); additive hypotensive agents (other antihypertensives); clinical review when statins or antiarrhythmics are co‑prescribed.
• Practical action: Check interaction tools for polypharmacy, review dosing and counsel patients about grapefruit and alcohol.

Vigilance is advised especially in older adults on multiple medicines.

Comparable medicines and prescribing preferences

When might a clinician choose a different calcium‑channel blocker or another class instead of amlodipine?

Close comparators in NHS practice include other dihydropyridine CCBs such as lercanidipine, felodipine and nifedipine, and alternative classes like ACE inhibitors, ARBs and thiazide‑like diuretics.

Choice depends on age, ethnicity, comorbidities and side‑effect profile; amlodipine’s long half‑life and once‑daily dosing favour adherence, but it has higher rates of peripheral oedema compared with some alternatives.

Where oedema is problematic, options include dose reduction, combining with an ACE inhibitor or ARB to mitigate swelling, or switching to a different class where clinically appropriate.

Fixed‑dose combination pills (amlodipine plus ARB or statin) can simplify regimens and improve adherence, but local formulary status influences availability.

• Pros: Once‑daily dosing, reliable BP lowering, useful in angina.
• Cons: Dose‑related peripheral oedema, possible drug interactions via CYP3A4.

Frequently asked questions

Q: Will amlodipine make me feel dizzy?

A: Some people experience dizziness or flushing, especially when starting or increasing the dose; avoid driving until you know how it affects you and consult your pharmacist or GP.

Q: What if my ankles swell?

A: Peripheral oedema is a common dose‑related side effect; contact your GP or pharmacist — options include dose adjustment, reviewing other medicines, or switching drug class.

Q: Can I drink alcohol or grapefruit juice?

A: Moderate alcohol may increase dizziness; large amounts of grapefruit juice can affect drug metabolism and are best avoided.

Q: Is it safe in pregnancy?

A: Discuss with your GP or specialist — data are limited and specialists often prefer alternatives with stronger pregnancy safety data.

Guidelines for proper use

What should pharmacists cover at the point of supply and during follow‑up?

Confirm the indication and explain once‑daily timing, advising patients to take amlodipine at the same time each day to support adherence.

Explain common side effects such as peripheral oedema, dizziness and flushing, and advise on missed doses (take as soon as remembered unless the next dose is due soon; do not double up).

Check concomitant medicines and alcohol intake, and flag urgent symptoms that need immediate review such as syncope, worsening chest pain or sudden severe breathlessness.

Signpost NHS resources including the NHS.UK medicines pages, MHRA patient leaflets and NHS 111 for out‑of‑hours advice.

Storage advice: keep in original packaging, below 25°C, away from moisture and light.

• Pharmacist checklist: Confirm indication; review other medicines for CYP3A4 interactions; counsel on oedema and dizziness; document counselling and encourage follow‑up in 2–4 weeks.
• Repeat prescribing: Encourage use of the NHS Electronic Prescription Service (EPS) and electronic repeat prescriptions to streamline dispensing at community pharmacies.

Delivery across the United Kingdom

Final practical notes

Amlodipine is a well‑established choice for hypertension and angina in NHS practice, with reliable once‑daily dosing and proven outcome benefits when used appropriately.

Monitor for dose‑related peripheral oedema and counsel patients to report swelling, dizziness or unusual symptoms promptly.

Check for CYP3A4 inhibitors and commonly used antihypertensives to avoid interaction‑related adverse events.

Generics are the common NHS choice, while the branded option Istin remains available where clinically indicated.

In our online pharmacy, amlodipine is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

For further patient information consult NHS.UK medicine leaflets and the MHRA guidance on calcium‑channel blockers.